Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 179,831,120
  • Shares Outstanding, K 538,481
  • Annual Sales, $ 33,424 M
  • Annual Income, $ 4,090 M
  • EBIT $ 8,671 M
  • EBITDA $ 14,263 M
  • 60-Month Beta 0.45
  • Price/Sales 5.34
  • Price/Cash Flow 10.91
  • Price/Book 18.56

Options Overview Details

View History
  • Implied Volatility 22.31% (+0.99%)
  • Historical Volatility 21.73%
  • IV Percentile 20%
  • IV Rank 10.65%
  • IV High 50.37% on 04/08/25
  • IV Low 18.97% on 02/20/25
  • Expected Move (DTE 6) 5.06 (1.52%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 3,047
  • Volume Avg (30-Day) 8,792
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 124,590
  • Open Int (30-Day) 150,032
  • Expected Range 327.87 to 337.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 4.74
  • Number of Estimates 11
  • High Estimate 5.52
  • Low Estimate 4.49
  • Prior Year 5.31
  • Growth Rate Est. (year over year) -10.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
312.39 +6.58%
on 12/11/25
346.38 -3.88%
on 12/03/25
-11.64 (-3.38%)
since 11/26/25
3-Month
270.67 +23.00%
on 09/29/25
346.38 -3.88%
on 12/03/25
+59.95 (+21.96%)
since 09/26/25
52-Week
257.05 +29.52%
on 01/06/25
346.38 -3.88%
on 12/03/25
+69.75 (+26.50%)
since 12/26/24

Most Recent Stories

More News
Dogs of the Dow Enhanced Income Strategy with Covered Calls

The Dogs of the Dow has long been a simple, rules-based approach to equity investing, built around owning the highest-yielding stocks in the Dow Jones Industrial Average. Each year, investors rotate into...

VZ : 40.48 (+0.40%)
CVX : 150.02 (-0.32%)
KO : 69.87 (-0.34%)
MRK : 106.78 (+0.31%)
PG : 144.74 (+0.17%)
JNJ : 207.63 (-0.07%)
NKE : 60.93 (+1.55%)
HD : 349.78 (+0.70%)
AMGN : 332.93 (-0.31%)
UNH : 331.83 (+1.30%)
Trump announces lower drug price deals with 9 pharmaceutical companies

U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead...

AZN.LN : 13,673.998 (-0.45%)
GILD : 124.70 (-0.77%)
AMGN : 332.93 (-0.31%)
PFE : 25.09 (+0.24%)
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing

AMGN : 332.93 (-0.31%)
3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.

SYK : 354.22 (-0.15%)
JNJ : 207.63 (-0.07%)
LLY : 1,077.75 (+0.07%)
AMGN : 332.93 (-0.31%)
1 Dow Jones Stock Worth Your Attention and 2 We Brush Off

1 Dow Jones Stock Worth Your Attention and 2 We Brush Off

VZ : 40.48 (+0.40%)
HD : 349.78 (+0.70%)
AMGN : 332.93 (-0.31%)
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS

UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*

AMGN : 332.93 (-0.31%)
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND

THOUSAND OAKS, Calif. , Dec. 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026. The dividend...

AMGN : 332.93 (-0.31%)
2 Momentum Stocks for Long-Term Investors and 1 We Brush Off

2 Momentum Stocks for Long-Term Investors and 1 We Brush Off

OSIS : 269.82 (+0.05%)
AMGN : 332.93 (-0.31%)
KEY : 21.19 (+0.24%)
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

NVDA : 190.53 (+1.02%)
XLV : 156.05 (+0.16%)
JNJ : 207.63 (-0.07%)
LLY : 1,077.75 (+0.07%)
IBB : 172.03 (-0.70%)
GILD : 124.70 (-0.77%)
REGN : 784.97 (+0.16%)
AMGN : 332.93 (-0.31%)
UNH : 331.83 (+1.30%)
Is Bristol-Myers Stock Underperforming the S&P 500?

Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.

$SPX : 6,929.94 (-0.03%)
AMGN : 332.93 (-0.31%)
BMY : 54.64 (-0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 337.45
2nd Resistance Point 335.72
1st Resistance Point 334.32
Last Price 332.93
1st Support Level 331.19
2nd Support Level 329.46
3rd Support Level 328.06

See More

52-Week High 346.38
Last Price 332.93
Fibonacci 61.8% 312.26
Fibonacci 50% 301.71
Fibonacci 38.2% 291.17
52-Week Low 257.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar